UNSPSC 51161534: Denbufylline

This classification denotes a phosphodiesterase inhibitor with the molecular formula C16H24N4O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 04B949KO6F, chemically known as 3,7-dihydro-1,3-dibutyl-7-(2-oxopropyl)-1h-purine-2,6-dione but generally known as denbufylline, which bears US NIH Compound Identifier 2984. European Medicines Agency schedules Denbufylline in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06974MIG. The term DENBUFYLLINE is an International Non-Proprietary Name.

UNSPSC 51161534 Denbufylline, a Commodity code, encompasses pharmaceutical active ingredients and finished products supplied through state and local cooperative purchasing agreements, specifically generic multi-source pharmaceuticals and over-the-counter products distributed to state facilities, counties, municipalities, and other public bodies. The scope includes branded and generic drugs, OTC medications, and related pharmaceutical products procured at volume discounts through established wholesaler networks and administered as multi-award cooperative agreements. State and local procuring entities access these agreements rather than conducting individual solicitations, leveraging cooperative purchasing vehicles such as the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) to negotiate pricing, establish chargeback terms, and manage supply chain compliance across participating jurisdictions.

The Minnesota Department of Administration's Office of State Procurement administers MMCAP, which includes participating state entities and local government facilities in Minnesota and Oregon. The most recent representative opportunity is MMCAP's Request for Proposal S1070000015802 for Generic Multi Source Pharmaceuticals and OTC Products, posted January 20, 2026, with proposals due March 26, 2026. The RFP requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—with comprehensive pricing submission by National Drug Code, SKU, UPC, and packaging configuration. Evaluation weighs price competitiveness at 75 percent, with the remainder split across fixed pricing, administrative-fee compliance, EDI capability, and administrative-fee acceptance. Vendors must maintain $5 million commercial general liability coverage, certify cGMP and Drug Supply Chain Security Act compliance, and contract with at least two of the three authorized wholesalers. Contract terms run two years for new responders with optional extensions, and incumbent responders' amendments extend through June 30, 2028. Award values and specific budget ranges are not disclosed; vendor performance is subject to penalties ranging from $200 to $1,500 per violation.